Richard Martin
About Richard Martin
Richard Martin serves as the Vice President of Technical Operations at Travere Therapeutics, where he specializes in drug discovery and development across various medical fields. He has held significant roles in organizations such as Exelixis, Targazyme, and Apricus Biosciences, contributing to the approval of important pharmaceutical products.
Work at Travere Therapeutics
Richard Martin has served as Vice President of Technical Operations at Travere Therapeutics since 2017. In this role, he oversees various technical operations, contributing to the company's efforts in drug development and commercialization. His responsibilities include managing the manufacturing processes and ensuring compliance with regulatory standards. His leadership in this position has been instrumental in advancing the company's pipeline and enhancing operational efficiencies.
Education and Expertise
Richard Martin holds a Ph.D. in Chemistry from the University of Toronto, obtained between 1991 and 1995. He also completed a Master of Science in Chemistry at Université Laval from 1989 to 1991, and a Postdoctoral fellowship at Scripps Research from 1995 to 1997. His educational background provides a strong foundation for his specialization in drug discovery and development, particularly in inflammation, oncology, virology, cardiovascular, and metabolic diseases.
Background in Pharmaceutical Operations
Prior to his current role, Richard Martin held significant positions in various pharmaceutical companies. He was the Director of Chemistry at Exelixis, Inc. from 2004 to 2009, where he contributed to drug development initiatives. He also acted as Vice President of CMC and Head of Operations at Targazyme. His experience includes directing Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs), enhancing his operational expertise in the pharmaceutical sector.
Achievements in Drug Development
Richard Martin has a proven track record in drug development, notably directing the CMC and regulatory work that led to the approval of Apricus Biosciences' first drug, Vitaros, in Canada and Europe. He has managed manufacturing, CMC, and supply chain for Apricus' internal pipeline, which includes both clinical and commercial products. He has successfully brought multiple compounds into clinical development, with four compounds currently in the clinic.
Experience in Intellectual Property
Richard Martin possesses expertise in intellectual property and patent filings related to pharmaceutical innovations. His knowledge in this area supports the strategic development of new drug candidates and enhances the competitive positioning of the organizations he has worked with. This expertise is crucial in navigating the complexities of pharmaceutical development and securing the necessary protections for new inventions.